VivoSeq
Cardiovascular

Cardiotoxicity

41

Pipeline Programs↗

17

Active Trials↗

17

Companies Involved↗

Cardiotoxicity is a moderately active landscape with 41 programs across 17 companies. The most active players are Monyan Pharmaceutical (Shanghai) Co., Ltd., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Vitae Pharmaceuticals Inc., an Allergan affiliate. 5 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

15/100

Mech. Concentration

16/100

Completion Rate

96/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Monyan Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2J

Jagotec

1 program

Phase 2Teva logo

Teva

1 program

Phase 3V

Viking Therapeutics, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

50 of 51 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody12%

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Analysis

Trial Status

54

clinical trials

Completed23 · 43%
Unknown status13 · 24%
Recruiting11 · 20%
Not yet recruiting4 · 7%
Enrolling by invitation1 · 2%
Active, not recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

54 trials

Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Recruiting·—·Phase 3·NCT06853951·30 enrolled
Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Recruiting·TTanta University·Phase 2·NCT07137793·46 enrolled
Cardiotoxicity in Breast Cancer Patients
Recruiting·HHelwan University·Phase 4·NCT06491680·40 enrolled
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Recruiting·UUniversity Medical Centre Ljubljana·Phase 2·NCT07245069·100 enrolled
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 3·NCT05271162·220 enrolled
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
Recruiting·CCentre Paul Strauss·N/A·NCT06443645·50 enrolled
Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
Recruiting·—·Phase 2·NCT07233499·56 enrolled
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT06341842·316 enrolled
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Recruiting·SSilesian Centre for Heart Diseases·Phase 4·NCT05465031·600 enrolled
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Recruiting·GGeorgetown University·Phase 1/2·NCT05256745·48 enrolled
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
Recruiting·BBeneficência Portuguesa de São Paulo·N/A·NCT07663357·1,000 enrolled
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06844669·7 enrolled
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Not yet recruiting·UUniversity of Aberdeen·N/A·NCT07070765·70 enrolled
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Not yet recruiting·TTanta University·Phase 1/2·NCT07370506·36 enrolled
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Not yet recruiting·—·Phase 1/2·NCT06684509·46 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)